by Lupus is a chronic autoimmune disease in which the immune system of the body mistakenly attacks healthy tissues and organs. Lupus can affect various parts of the body including joints, skin, kidneys, blood cells, brain, heart, and lungs. Growing prevalence of autoimmune disorders such as lupus has propelled the demand for effective lupus therapeutics. Lupus therapeutics aid in reducing symptoms, preventing flares and organ damage. Increasing healthcare expenditure and R&D efforts by key players for developing innovative targeted therapies have also supported market growth.
The global Lupus Therapeutic Market is estimated to be valued at US$ 30 billion in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence autoimmune disorders is a major trend driving the growth of the lupus therapeutic market. According to the Lupus Foundation of America, around 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. It generally affects women of childbearing age more than men. With growing global population and increasingly sedentary lifestyle, the prevalence of autoimmune conditions such as lupus is expected to rise substantially over the coming years. This will augment the demand for effective treatment and management of the disease via lupus therapeutics during the forecast period.
SWOT Analysis
Strength: Lupus therapeutic drugs are more effective in controlling disease symptoms and flare-ups compared to conventional treatments. Newer targeted biological drugs have fewer side effects.
Weakness: High cost of lupus biologics limits widespread adoption. Late diagnosis remains a challenge in many regions.
Opportunity: Growing awareness about lupus care and management presents opportunities for drug makers. Expanding patient support programs can boost treatment rates.
Threats: Patent expiries of blockbuster lupus drugs will increase competition. Strict regulations for biosimilars approval poses delay risks.
Key Takeaways
The Global Lupus Therapeutic Market Size is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: North America dominates the lupus therapeutics market currently due to strong diagnostic rates, availability of advanced treatments, and high patient awareness. The Asia Pacific region is anticipated to grow at the fastest pace during the forecast period driven by rising lupus prevalence, increasing research focus, and growing healthcare expenditure.
Key players operating in the lupus therapeutic market are GlaxoSmithKline, Pfizer, AstraZeneca, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Anthera Pharmaceuticals, Immunomedics
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
